Multiple direct submissions to ABOUT Network from community and enrollees
There is a strong interest from members of the community for more research to better clarify cancer risk with different mutations. Even for BRCA1 and BRCA2 mutations, which have been studied for over 20 years, risk assessment is not as accurate as people wish. This is even more apparent with newly identified mutations such as PALB2 and CHEK2 among others.
ABOUT has received several research questions submitted by community members around the following themes related to risk assessment:
This question has not yet gone through GAP Tools prioritization process.
This question has not yet gone through GAP Tools feasibility scoring process.
Previvors/High risk people
People with a BRCA mutation
People with an ATM, PALB2, PTEN, or other mutation that increases cancer risk
People with Lynch Syndrome
People at high risk for breast cancer
People at high risk for ovarian cancer
People who are newly diagnosed with cancer